Dear Editor,
This study wishes to bring to the attention of your readers the ocular signs and symptoms
of Monkeypox infection and the possible involvement of the eye in the transmission
of this virus.
Monkeypox is a zoonotic disease caused by a member of the Poxviridae family called
the monkeypox virus (MPXV). Before May 2022, infections with this virus were limited
to Africa, where it is endemic [1]. In the middle of 2022, a sudden multinational
outbreak of MPXV was reported that led the World Health Organization (WHO) to declare
the disease a pandemic. There have been 71,437 laboratory-confirmed cases and 29 deaths
as of 19th October 2022 [2].
MPVX is commonly spread by respiratory droplets, contact with bodily fluids, and skin
lesions from an infected individual [1]. In the endemic areas of MPXV infections,
ocular involvement has been reported in both the early and late stages of the disease.
In the early stages, 71 % of patients have enlarged lymph nodes including the pre-auricular
nodes [3], and 25 % have a vesicular rash involving the orbital and peri-ocular skin
[4]. Blepharitis and conjunctivitis have been reported in 30 % of unvaccinated and
7 % of vaccinated patients [5] and focal conjunctival lesions occur in 17 % of unvaccinated
compared and 14 % of vaccinated patients [6]. In the later stages of the disease,
22.5 % of patients complain of photophobia [4], up to 7.5 % develop keratitis [4],
[7], corneal ulceration occurs in 4 % of unvaccinated and 1 % of vaccinated patients
[7], and up to 10 % of cases can result in vision loss [7].
A literature search was performed of four electronic databases (PubMed, Scopus, Google
Scholar, and Chinese biomedical database (CNKI)) using the keyword search terms “monkeypox”
AND “ocular” OR “eyes”. As of 22nd September 2022, there have been six reports of
MPXV isolated from ocular swabs, and several cases with ocular signs and symptoms.
It appears that the first publication of ocular involvement in the current pandemic
was published in July 2022 [8]. The last two cases contained in this article were
from the USA and reported by the Centers for Disease Control and Prevention (CDC)
on October 17, 2022 [9]. Table 1
summarises all cases reporting the isolation and identification of the monkeypox virus
from the eyes to October 2022. The most common ocular events produced by this virus
are conjunctivitis (red eyes), itchiness, pain, photophobia, and vision changes very
similar to those previously reported for earlier endemic cases [4], [5], [6], [7].
Conjunctivitis (Fig. 1
A–B) often with ulceration and with umbilicated papillae on the tarsal and bulbar
conjunctiva, the fornix, and at the temporal limbus (Fig. 1C–D) can appear some days
(2–7 days) after the appearance of rashes on other parts of the body [8], [9], [10],
[11]. Ocular signs and symptoms may last for 1–2 months.
Table 1
Overall summary of cases reporting the presence of monkeypox virus in ocular sites.
Case No. and reference
Gender
Age(years)
Country
Dateof publication
Ocular signs and symptoms
Collection site
Virus detection method*
Ocular Treatment and time to resolution
1 [8]
Male
39
Italy
July 29, 2022
Conjunctivitis of the left eye; a small vesicle on the lower eyelid; resolved into
a single whitish ulcer (10 mm) on the medial bulbar conjunctiva, with regular edges.
Swabs of ocular vesicles
PCR
Neomycin (3500 IU/mL), polymyxin B (6000 IU/mL), and dexamethasone (1 mg/mL).After
3 weeks the ocular vesicles were no longer visible and the eye had almost healed,
although some redness remained.
2 [10]
Male
39
–
August 13, 2022
Red-eye; itchiness; conjunctival follicular reaction with small white vesicles on
the nasal bulbar conjunctiva.
Swabs of conjunctiva and eye secretion
PCR
–
3 [11]
Male
26
Italy
August 17, 2022
Multiple papular lesions in the right eyelid with progressive periorbital and conjunctival
involvement
Swabs of eyelid and conjunctiva
RT-PCR, cell culture
Initially intravenous antibiotic therapy with topical steroid therapy. Changed to
cidofovir (5 mg/kg weekly with oral probenecid and fluid support), anti-inflammatory,
and vitamin A-based eye drops. Steroid local therapy was stopped.Resolved approximately-two
months after onset.
4 [12]
Male
35
Italy
August 27, 2022
Unilateral ocular pain and photophobia, multiple umbilicated papillae on the tarsal
and bulbar conjunctiva, the fornix, and at the temporal limbus. The fellow eye was
uninvolved.
Conjunctival swab
RT-PCR
Ocular papillae resolved in 3 days following the administration of a single intravenous
dose of cidofovir (5 mg/kg).
5 [13]
Male
42
–
September 7, 2022
Left-eye lacrimation, pain, and photophobia, with ulcers on the eyelid margin, mucoid
whitish conjunctival discharge, and serpiginous infiltrative lesions with conjunctival
thickening.Conjunctival pseudomembranes developed in the second week of treatment,
which was removed.
Conjunctival swab
PCR
Systemic treatment with 600 mg tecovirimat every 12 h and intravenous acyclovir, 1 g
every 8 h, plus topical zinc sulfate every 8 h on the skin lesions. Ocular topical
treatment with 0.2 % chlorhexidine, 0.5 % ganciclovir, moxifloxacin (dose unknown),
and 1 % povidone-iodine eye drop, applied 5 times a day. Topical fluorometholone treatment
4 times a day started after the appearance of pseudomembranes. Conjunctival lesions
resolved after 4 weeks.
6 [9]
Male
20–29
USA
October 17, 2022
Initially pain, itching, swelling, discharge, foreign body sensation, photosensitivity,
and vision changes (20/40) for the left eye (resolved with treatment).One month later
presented with conjunctivitis, keratitis, and a vision of 20/300 in the left eye.
ConjunctivalSwab
PCR; immuno-histochemistry
Intravenous tecovirimat and topical trifluridine with antiretroviral therapy (ART).
Discharged once ocular symptoms improved, and advised to take regular medication (oral
tecovirimat, topical trifluridine, and ART). After reoccurrence, intravenous tecovirimat
with one week’s course of topical trifluridine and povidone-iodine for the left eye.
At the time of writing status and any vision recovery unspecified.
7 [9]
Male
30–39
USA
October 17, 2022
rashes with symptoms of redness, pain, and eyelid swelling on the right eye.
Eye swab
PCR
Initially, empiric antibiotics for suspected bacterial infection. After two days,
trifluridine for 5 days; antibacterial drops to the right eye. Oral tecovirimat (14-day
course) after discharge
*
PCR = polymerase chain reaction; RT-PCR = real time polymerase chain reaction.
Fig. 1
Ocular manifestations of monkeypox virus infection. 1Figure A–B Reprinted from Ophthalmology,
Vol 129 Issue 10, Meduri, E., A. Malclès, and M. Kecik, Conjunctivitis with Monkeypox
Virus Positive Conjunctival Swabs, Pages No. 1095, Copyright (2022), with permission
from Elsevier. 2Figure C–D Reprinted from Ophthalmology, Vol 129 Issue 11, Scandale,
P., A.R. Raccagni, and S. Nozza, Unilateral Blepharoconjunctivitis due to Monkeypox
Virus Infection, Pages No. 1274, Copyright (2022), with permission from Elsevier.).
Along with ocular signs and symptoms, this report outlines the possibility of viral
transmission from ocular sites. Seven cases were reported detecting MPXV nucleic acid
from ocular sites. Eye care practitioners should follow protective and prophylactic
measures and be aware of the general and ocular signs and symptoms, as well as patient
histories (for example the current outbreak appears to be commonly associated with
men who have sex with men, but that could change if the pandemic intensifies) that
can help diagnose the disease and stop transmission. Ocular involvement in the monkeypox
virus pandemic demands more attention from the researcher and believe this work will
grab the attention of those who have an interest in viral eye infections.
Funding statement
This research did not receive any specific grant from funding agencies in the public,
commercial, or not-for-profit sectors.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal
relationships that could have appeared to influence the work reported in this paper.